Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Sep 29;6(29):28071-83.
doi: 10.18632/oncotarget.4872.

FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer

Hou-Qun Ying  1   2 , Feng Wang  2 , Xiao-Lin Chen  3 , Bang-Shun He  2 , Yu-Qin Pan  2 , Chen Jie  2   4 , Xian Liu  2 , Wei-Jun Cao  5 , Hong-Xin Peng  1 , Kang Lin  2 , Shu-Kui Wang  2
Affiliations
Meta-Analysis

FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer

Hou-Qun Ying et al. Oncotarget. .

Abstract

Anti-EGFR monoclonal antibodies (mAb) such as cetuximab, panitumumab are one kind of efficacious targeted drugs in treatment of metastatic colorectal cancer (mCRC). However, only a small proportion of patients harbored wild-KRAS genotype can benefit from it. We hypothesized that personal genetic heterogeneity might be the main cause leading to obvious difference in its clinical efficacy. A retrospective study including 82 mCRC patients treated with chemotherapy plus cetuximab and a comprehensive meta-analysis containing 2831 cases within sixteen eligible studies were conducted to investigate the possible association between FCGR2A H131R and FCGR3A V158F and clinical outcome of mCRC patients treated with anti-EGFR mAb based therapy. Results of the retrospective study showed that H131R within FCGR2A or V158F within FCGR3A were not associated with clinical outcome in 82 KRAS wild chemorefractory mCRC patients in co-dominant, dominant, recessive, over-dominant, allele genetic models. However, the comprehensive meta-analysis with the largest of sample size obtained the significant result between FCGR3A V158F and PFS (FV/VV vs. FF: Ph = 0.027, MSR = 0.680, 95%CI = 0.549-0.842 in overall population; Ph = 0.12, MSR = 0.728, 95%CI = 0.648-0.818 in KRAS wild population) and OS (VV vs. FF: Ph < 0.001, MSR = 0.733, 95%CI = 0.578-0.930 in overall population). These findings indicate that KRAS wild chemorefractory mCRC individual harbored genotype FF of V158Fcan benefit from anti-EGFR mAb adjuvant therapy in terms of PFS and OS, and it may be useful genetic biomarker to predict clinical survival of mCRC individuals with anti-EGFR mAb based therapy.

Keywords: F158V; FCGR; H131R; anti-EGFR mAb; mCRC.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors have declared no conflict of interests with respect to the authorship and/or publication of this article.

Figures

Figure 1
Figure 1. Kaplan-Meier curves for FCGR2A H131R and FCGR3A V158F for progression-free survival and overall survival
A. H131R for PFS; B. V158F for PFS; C. H131R for OS; D. V158F for OS.
Figure 2
Figure 2. Meta-analysis result of association between FCGR3A V158F and progression-free survival and overall survival in mCRC patients treated with anti-EGFR mAb based therapy
A. FV/VV vs. FF for PFS in overall population; B. FV/VV vs. FF for PFS in KRAS wild population; C. VV vs. FF for OS in overall population.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chen W, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015;27:2–12. - PMC - PubMed
    1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–117. - PubMed
    1. Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther. 2013;35:1282–1303. - PubMed
    1. Benson AB, 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, et al. Colon cancer, version 3. 2014. J Natl Compr Canc Netw. 2014;12:1028–1059. - PubMed
    1. Cheng L, Ren W, Xie L, Li M, Liu J, Hu J, Liu BR, Qian XP. Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. Cancer Chemother Pharmacol. 2014;74:1–13. - PubMed

Publication types

MeSH terms